

Daicel launches pyro-drive jet injector Actranza™ lab. at ASGCT 2019

April 29, 2019 - Daicel's Medical Device Division will introduce its Pyro-drive Jet Injector **Actranza™ lab.** for Intracellular Drug Delivery while attending the 22nd Annual Meeting of The American Society of Gene & Cell Therapy, April 29 – May 1, 2019 in Washington D.C.

Actranza™ lab. was developed to deliver nucleic acid-based drugs, including DNA vaccines, into living cells, via a minimally invasive jet injection device. The high-speed stream of fluid ejected by Actranza™ lab. penetrates skin, dispersing delivered molecules into intradermal tissue with the potential of introducing large molecules into cells.

This device has been currently developed for research use only in laboratory animal testing. The ultimate goal is to establish a brand-new technology for Drug Delivery Systems (DDS), which will lead to innovative pharmaceuticals, such as in vivo gene therapeutics, oligonucleotide therapeutics or DNA vaccines. Daicel aims to identify beta-testing partners during the conference and promote research into human applications.

The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting provides an international forum where the latest gene and cell therapy developments are presented and critically discussed. ASGCT's annual meeting brings together more than 3,400 professionals including scientists, physicians, and patient advocates.

<https://www.asgct.org/events/annual-meeting>

Daicel Corporation, Booth 423